US EditionAbbVie To Present Cancer Trial Data At Upcoming ASCO Event - AbbVie (NYSE:ABBV)
- AbbVie revealed that it will share important findings from its oncology research, including data on experimental antibody-drug conjugates, at the upcoming ASCO conference scheduled to take place in Chicago from May 30 through June 3, 2025.
- This event follows clinical trials evaluating ADC therapies like telisotuzumab adizutecan for advanced NSCLC and PVEK for blastic plasmacytoid dendritic cell neoplasm, responding to unmet cancer treatment needs.
- Preliminary phase 1 data from 41 patients with pre-treated EGFR-mutated NSCLC showed Temab-A achieved a 63% objective response rate with manageable safety, while PVEK demonstrated a 70% composite complete response rate in untreated BPDCN patients.
- Ross Camidge described Temab-A’s anti-tumor activity as "encouraging and supports further exploration," and Roopal Thakkar emphasized the data reflect AbbVie’s oncology pipeline breadth and research commitment.
- These results suggest potential clinical benefits for difficult-to-treat cancers and reinforce AbbVie’s commitment to advancing targeted therapies amid risks and uncertainties outlined in their 2024 Annual Report.
15 Articles
15 Articles
Farm Talk Newspaper
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic…
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - AbbVie (NYSE:ABBV)
AbbVie Inc (NYSE:ABBV) stock is trending on Tuesday after the U.S. drug giant announced that key data from its broad oncology portfolio will be showcased at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. An oral presentation on investigational elotuzumab adizutecan (ABBV-400, Temab-A), a next-generation, c-Met directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) payload, will showcase: …
AbbVie to spend $6 Million to occupy 14,692 square feet of space in Austin Texas.
Austin, Texas — According to state and local development sources, AbbVie plans to invest $6 Million to build out 14,692 square feet of new space in Austin. The company plans to occupy the new space at 12301-A Riata Trace Pkwy, Bldg 3, Suite 100 in Austin, on or about December 1, 2025. According to the company website AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first for patients, commu…
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Life Sciences British Columbia
AbbVie shares key data that highlight significant progress in its robust oncology pipeline, across a range of solid tumors and blood cancers.
GlobalData forecasts ADC NSCLC market to reach $3.9 billion in 2032
Despite the FDA first approving Pfizer’s antibody-drug conjugate (ADCs) Mylotarg (gemtuzumab ozogamicin) in 2000, it was not until 2022 for non-small-cell lung cancer (NSCLC) to see its first ADC approval, AstraZeneca’s and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), for human epidermal growth factor receptor (HER) 2-mutated patients. Following this approval, the ADC market in NSCLC is projected to grow at a CAGR of 6.8% across the seven …
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
